ERBB2 and neoplasm: Consistent with this view, in preclinical tumour models of anti-Her2/neu-based mAb therapies, mice deficient in activating Fc receptors as well as antibodies engineered to disrupt Fc binding to those receptors were unable to arrest tumour growth in vivo (Clynes et al, 2000).